Papillary glioblastoma exhibiting a neuroradiological cyst with a mural nodule

DOI PubMed Open Access

Bibliographic Information

Other Title
  • A case report

Search this article

Description

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Rationale:</jats:title> <jats:p>Glioblastomas are malignant, infiltrating gliomas classified as grade IV by the World Health Organization. Genetically, most glioblastomas do not exhibit the isocitrate dehydrogenase (<jats:italic toggle="yes">IDH</jats:italic>) 1/2 gene mutation and rarely harbor the 1p/19q co-deletion. Neuroradiologically, glioblastomas rarely form a cyst with a mural nodule lesion.</jats:p> </jats:sec> <jats:sec> <jats:title>Patient concerns:</jats:title> <jats:p>In this study, a 78-year-old woman, with speech difficulty and forgetfulness, had a cystic tumor with a mural nodule in the right frontoparietal lobe. Therefore, partial tumor resection was performed.</jats:p> </jats:sec> <jats:sec> <jats:title>Diagnosis:</jats:title> <jats:p>Histopathology of the tumor, a glioblastoma, exhibited pseudopapillary features with non-hyalinized capillary cores and rich mini-gemistocytic cells. Genetic analysis of the tumor revealed co-deletion of 1p36/19q13, with wild-type <jats:italic toggle="yes">IDH</jats:italic>.</jats:p> </jats:sec> <jats:sec> <jats:title>Interventions:</jats:title> <jats:p>The patient underwent a combination of postoperative radiotherapy and temozolomide chemotherapy before leaving the hospital. After discharge, she was treated by 20 courses of temozolomide chemotherapy.</jats:p> </jats:sec> <jats:sec> <jats:title>Outcomes:</jats:title> <jats:p>The patient is free from tumor recurrence 23 months after the operation.</jats:p> </jats:sec> <jats:sec> <jats:title>Lessons:</jats:title> <jats:p>We present a unique case of glioblastoma that exhibited novel neuroradiological, histopathological, and genetic features with a favorable prognosis for the patient. Therefore, a compilation of similar cases with clinicopathological and genetic analyses to characterize this unique glioblastoma is critical. Clinical evidence will help develop effective therapeutic approaches to improve prognosis in patients with glioblastoma.</jats:p> </jats:sec>

Journal

  • Medicine

    Medicine 98 e14102-, 2019-01-01

    Ovid Technologies (Wolters Kluwer Health)

Details 詳細情報について

Report a problem

Back to top